Wall Street analyst estimates for Lexaria Bioscience Corp. (LEXX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 1.08 |
| EV / EBITDA | -0.43 |
| Dividend Yield | 0.00% |
Price
| Price | $3.10 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | CA |
Explore sector: Healthcare · Biotechnology
More sections of LEXX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks